Trials / Active Not Recruiting
Active Not RecruitingNCT03467867
A Study of Venetoclax and Rituximab/Hyaluronidase Human in Relapsed/Refractory CLL
A Phase II Study of Venetoclax and Rituximab/Hyaluronidase Human in Relapsed/Refractory CLL
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 25 (actual)
- Sponsor
- Georgetown University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is an open-label, multicenter, Phase II study to investigate the efficacy and safety of venetoclax in combination with Rituximab/hyaluronidase human in participants with relapsed or refractory chronic lymphocytic leukemia (CLL).
Detailed description
The study has one arm and all the patients will receive venetoclax and rituximab.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Venetoclax | Venetoclax will be administered as described in the reporting arm. |
| DRUG | Rituximab | Rituximab (IV) will be administered as described in the reporting arm. |
| DRUG | Rituximab/Hyaluronidase Human | Rituximab/Hyaluronidase Human (SC) ill be administered as described in the reporting arm. |
Timeline
- Start date
- 2018-04-26
- Primary completion
- 2026-12-01
- Completion
- 2026-12-01
- First posted
- 2018-03-16
- Last updated
- 2026-04-06
Locations
2 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03467867. Inclusion in this directory is not an endorsement.